Description

How This Works

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1^[4]. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via central nervous system effects, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion^[1][3]. The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing^[1]. Clinical trials have demonstrated significant weight loss (mean 10–15% body weight reduction) in individuals with obesity when combined with lifestyle interventions^[1][5]. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach^[3][4].

Potential Benefits & Side Effects

Observations from clinical literature and regulatory approvals^[1][3][5].

Potential Benefits:

• Significant weight loss (mean 10–15% body weight reduction in clinical trials at 2.4 mg weekly dose) when combined with lifestyle modifications^[1][5].
• Improved glycemic control through enhanced glucose-dependent insulin secretion and reduced glucagon secretion^[3].
• Reduced appetite and food intake via central nervous system GLP-1 receptor activation^[1].
• Cardiovascular benefits demonstrated in outcome trials, including reduced risk of major adverse cardiovascular events^[6].
• Convenient once-weekly dosing improves adherence compared to daily regimens^[1].

Potential Side Effects:

• Gastrointestinal effects (most common): nausea, vomiting, diarrhea, constipation, abdominal pain—typically mild to moderate and decreasing with gradual dose escalation^[1][3].
• Injection-site reactions: redness, swelling, or irritation (generally mild and transient)^[11].
• Hypoglycemia risk (when combined with insulin or sulfonylureas)—less common with Semaglutide monotherapy due to glucose-dependent mechanism^[3].
• Rare serious adverse events: pancreatitis, gallbladder disease, acute kidney injury; thyroid C-cell tumors observed in rodent studies (relevance to humans uncertain)^[4].

Lifestyle Factors

Complementary strategies for optimal outcomes with GLP-1 therapy^[1][5].

• Maintain a balanced, calorie-controlled diet with adequate protein intake (1.2–1.6 g/kg body weight) to preserve lean muscle mass during weight loss.
• Combine regular physical activity including both resistance training (2–3 days per week) and aerobic exercise (150+ minutes per week) to reinforce metabolic adaptations and improve body composition.
• Prioritize consistent sleep (7–9 hours nightly) and effective stress management to support adherence and metabolic health.
• Stay well-hydrated (8–10 glasses of water daily), especially if experiencing gastrointestinal side effects.
• Monitor progress through regular weigh-ins, body measurements, photos, and consultation with healthcare providers.
• Consider working with a registered dietitian for personalized nutrition guidance during weight loss.